Welcome to CD BioSciences
Banner

Dendrimer-T7 Conjugation Service

Dendrimer-T7 Conjugation Service

HAIYPRH (T7) peptide can target transferrin receptor (TfR), when dendrimer binds to T7, it can easily enter cells with the help of transferrin (Tf), which not only improves transfection efficiency but also enhances targeting to tumor cells. CD BioSciences has advanced facilities and experienced scientists to provide high quality T7 binding to dendrimers.


Transferrin (Tf)

Transferrin and Transferrin Receptor

Targeting tumor cells through chemotherapy is the most effective way to inhibit tumor cell growth and treat cancer. However, the application of current drug delivery systems is limited due to poor targeting and significant side effects. The main strategies to improve the targeting of drug delivery systems are enhanced cell permeability, retention (EPR) effects and receptor-mediated endocytosis. In addition, ligand-mediated drug delivery systems have been shown to be a more effective tumor cell targeting strategy that can not only specifically identify tumor cells but also deliver drugs to cells via receptor-mediated endocytosis. Many receptors such as transferrin receptor (TfR), epidermal growth factor receptor and vascular endothelial growth factor receptor-2 are overexpressed in tumor cells and are associated with cell growth and survival. Current ligands used to enhance the targeting of drug delivery systems include galactose, folate, transferrin (Tf), and insulin, among others.

These ligands target receptors that are overexpressed by tumor cells and enable signal transduction by triggering endocytosis. Because tumor cells urgently need iron to survive, TfR is expressed in tumor cells at approximately 100-fold higher levels than in normal cells. Binding of iron loaded Tf to TfR triggers cellular endocytosis. HAIYPRH (T7), the most widely studied targeting agent for TfR, also known as HAIYPRH, is a peptide screened on cells expressing the human transferrin receptor through a phage display system. T7 not only exhibits a higher affinity for TfR, but also binds to TfR at a site different from that of Tf to TfR, and thus endogenous Tf does not inhibit the T7-modified drug delivery system.

Schematic diagram of detecting the cellular uptake of AuNP-T7 based on the force tracing technique.Schematic diagram of detecting the cellular uptake of AuNP-T7 based on the force tracing technique. (Li S, et al., 2021)

Dendrimer-T7 Conjugation

Nanocarriers provide an effective platform for targeted drug delivery when combined with ligands, allowing selective delivery of drugs to tumor cells. Nanomaterials used for targeted drug delivery include materials such as liposomes, micelles, and dendrimers. As one of the most attractive drug carriers, dendrimers are spherical, highly branched macromolecules, moreover, hyperbranched structures with a central core and flexible surface functions. The physical properties of dendrimers make them ideal candidates for drug delivery. The combination of dendrimers with T7, which can target human TrR, can enhance drug targeting for tumor therapy and gene delivery.

Our Services

As a fast growing and leading global provider of scientific research services and solutions, CD BioSciences offers you dendrimer-T7 conjugation services. We are committed to meeting all your detailed requirements and guarantee that all deliverables are subjected to rigorous quality testing.

Service Process

Advantages of Our Services

CD BioSciences is committed to helping our customers meet the growing and evolving demand for dendrimers products. We offer a wide range of services related to dendrimers and ensure quality and reliability of results as well as on-time delivery. If you are interested in our services or have any additional questions, please feel free to contact us, we are happy to hear from you and look forward to working with you.

Reference

  1. Li S.; et al. Revealing the Dynamic Mechanism by Which Transferrin Promotes the Cellular Uptake of HAIYPRH Peptide-Conjugated Nanostructures by Force Tracing. Mol Pharm.2021, 18: 1480-1485.

For research use only. Not for clinical use.